The Non-Malignant Haematology Specialty Group can support companies to set up and deliver studies on time.
The non-malignant haematology group works with the life sciences industry in the development of new therapies for NHS patients.
The members of the group have experience of successfully delivering commercial clinical studies in a variety of clinical settings.
Commercial studies, in both adults and children, that are potentially of interest to the group include those investigating:
- clotting factor concentrates
- therapies for ITP
- therapies for iron overload in haemoglobinopathies
- innovative iron replacement therapies.
This list is not exhaustive and any therapy that may represent an advance for NHS patients would be considered for inclusion on the non-malignant haematology portfolio.
The non-malignant haematology group has an ongoing collaboration with the National Haemophilia Database which maintains a record of patients with bleeding disorders within the UK. This enables the speciality group to advise on the incidence of bleeding disorders within the country as well as the location of patients around the country. Such information is anonymised, but can aid in the feasibility assessment of new commercial studies investigating novel therapies in this patient cohort. The group is happy to informally advise our commercial partners about aspects of study design within the UK, particularly regarding patient numbers and the likely location of patients within the UK.
What do we offer to Industry Research?
- A single point of contact for all our services
- Dedicated and trained Clinical Research Network staff and support services to assist with study delivery at site level
- Access to the NIHR Coordinated system for gaining NHS permission (NIHR CSP) for R&D approvals
- Support with study start-up processes and costing and contract negotiations, using standard templates
- Access to the NHS patient population
- Study and protocol feasibility from key opinion leaders and active commercial researchers
- Performance management of the adopted study in partnership with the company
- Clinical Research Network ‘badging’ of adopted trials to attract both investigators and patients
- Support to identify a broad range of investigators and research sites throughout the UK.